Active Biotech - Advancing Three Active Projects
2022-02-18 10:00:00
Redeye revisits its valuation of early-stage biotech company Active after significant progress across its three candidates, but also delays due to Covid-19. At the same time, we believe that the risk has increased slightly in tasquinimod.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/